H3R Inverse Agonist for Shift Work Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for shift work disorder, such as modafinil, have unfavorable risk-benefit profiles and fail to effectively address excessive sleepiness during night shifts, impacting cognitive function and quality of life, with ongoing sleepiness issues despite modest improvements in sleep latency.
Innovation Solution
Compound (I) or its pharmaceutically acceptable salt is used to treat shift work disorder by reducing excessive sleepiness, improving wakefulness, and enhancing cognitive function during night shifts without affecting daytime sleep, potentially offering a safer and more effective alternative.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If modafinil is used to treat shift work disorder, then wakefulness is improved, but safety profile deteriorates due to unfavorable risk-benefit ratio
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of modafinil to create Compound (I), which alters the pharmacological properties while maintaining wakefulness-promoting effects. This structural modification results in a compound that achieves similar therapeutic effects with an improved safety profile and favorable risk-benefit ratio compared to modafinil.
2Loss of time
If modafinil is used to treat excessive sleepiness, then sleep latency is improved modestly, but excessive sleepiness during night shifts persists
Solution Approach 1:
The patent applies parameter changes by developing Compound (I) with modified pharmacokinetic and pharmacodynamic properties that provide sustained wakefulness promotion throughout the night shift. The compound achieves this through its specific chemical structure and H3R inverse agonist mechanism, maintaining effective concentrations and therapeutic effects during extended periods when modafinil fails.
Solution Approach 2:
The patent uses copying by creating Compound (I) as a structural analog of modafinil, retaining the core pharmacophore features responsible for wakefulness promotion while modifying specific substituents to enhance duration and efficacy. This copied structure with modifications allows the compound to overcome the limitations of the original modafinil molecule.
3Productivity
If wakefulness-promoting agents are used during night shifts, then cognitive function is improved, but daytime sleep is affected
Solution Approach 1:
The patent applies local quality by designing Compound (I) to have selective action during night shift hours with a circadian-rhythm-aware pharmacokinetic profile. The compound's metabolism and elimination are optimized to clear from the system before daytime sleep periods, providing wakefulness promotion exactly when needed during night shifts while minimizing interference with subsequent daytime rest.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Compound (I) demonstrates significant improvements in wakefulness and cognitive function during night shifts, with a favorable safety profile compared to existing agents, effectively addressing excessive sleepiness and cognitive impairments associated with shift work disorder.
Implementation Method 1
Use of a H3R inverse agonist for the treatment of shift work disorder
Data Source
AI summary
The invention relates to the use of a H3R inverse agonist for the treatment of shift work disorder.